Dissemin is shutting down on January 1st, 2025

Published in

Taylor and Francis Group, Expert Opinion on Drug Delivery, 6(4), p. 621-633, 2007

DOI: 10.1517/17425247.4.6.621

Links

Tools

Export citation

Search in Google Scholar

Advances and challenges of nanotechnology-based drug delivery systems

Journal article published in 2007 by Wen Jiang ORCID, Betty Ys Kim, James T. Rutka, Warren Cw Chan
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

The ability to deliver highly efficient therapeutic compounds specifically to diseased sites is crucial for effectively treating all human illnesses. Unfortunately, conventional therapeutic strategies require unnecessarily high systemic administration due to non-specific biodistribution and rapid metabolism of free drug molecules prior to reaching their targeted sites. Using the tools of nanotechnology, drug delivery systems within the nanometer size regime can be developed to alter both pharmacological and therapeutic effects of drug molecules. Due to their small size, these novel DDS offer superior advantages, such as altered pharmacokinetic behaviour and improved payload, over traditional large-scale systems. In addition, the relative ease in modifying their surface chemistry permits the attachment of targeting and therapeutic molecules for specific therapeutic applications. Finally, complex nanostructures can be assembled using different building blocks with multiple functionalities ranging from targeting, detecting, imaging and therapeutic capabilities.